Ireland
--:--IST
Active, not recruiting Not applicable

Characterization of Bacterial and Mycosis Skin Flora in Seborrheic Macular Hypopigmentation - Microbiome

NCT06908889 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-06-25
Last updated
2026-09-29

Condition(s) studied

Hypopigmentation

Investigational drug(s) / intervention(s)

Skin's lesion patientsSkin's lesion vulunteers

Skin's lesion patients: Skin swabs will be obtained from the patient's facial lesional (FLS) and perilesional sites (FPS) using a sterile cotton swab. The microbiota of the same anatomical face regions will be collected on volunteers, once the 10 SMH patients have been enrolled. The swab is premoistened in a specific cocktail solution and rubbed onto the skin surface for 45sec. The pressure during the sampling involves rubbing the area of interest with a smear over the entire zone. The skin reddens slightly under the exerted pressure.

Skin's lesion vulunteers: Skin swabs will be obtained from the patient's facial lesional (FLS) and perilesional sites (FPS) using a sterile cotton swab. The microbiota of the same anatomical face regions will be collected on volunteers, once the 10 SMH patients have been enrolled. The swab is premoistened in a specific cocktail solution and rubbed onto the skin surface for 45sec. The pressure during the sampling involves rubbing the area of interest with a smear over the entire zone. The skin reddens slightly under the exerted pressure.

Study summary

Hypopigmented skin changes are commonly encountered by dermatologists. A new dermatological entity was identified as scattered, hypopigmented oval-shaped macules and patches distributed mostly in seborrheic area of the face and of the trunk in dark skinned individuals. This patterned presentation of hypopigmentation was first described in the literature under the name of hypochromic vitiligo or vitiligo minor. Nerveless, histopathological patient's specimens analyzed by Krueger et al. clearly highlight that there is no tangible causal correlation with a diagnosis of vitiligo. They propose to rename this entity to Seborrheic Macular Hypopigmentation (SMH). The etiopathology of this dermatosis is still unknown preventing to propose any satisfactory treatment for this disfiguring affection.The objective of this study is to analyze the bacterial and fungal skin microbiome on hypochromic lesions of SMH compared to the surrounding non-lesional skin of the same patients and to healthy volunteers

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Female and male patients ≥ 18 years of age 2. Clinical diagnosis of SMH with lesion of the face 3. Written informed consent obtained before any assessment is performed 4. Affiliation with a social security scheme 5. Physical and psychological ability to participate Exclusion Criteria: 1. Use of systemic antibiotics or any systemic antifungal treatments within 4 weeks before the inclusion visit 2. Use of topical antibiotics or any topical antifungal treatments on the face within 2 weeks before the inclusion visit 3. Use of any topical cream, gel, serum or ointment within 2 days before the inclusion visit 4. Laser, radiofrequency, peeling or any other procedure on the face in the past 3 months before the inclusion visit 5. Vulnerable patients: minors, patients under guardianship or curatorship, pregnant or breast-feeding women

Primary outcome measure(s)

  • The bacterial skin microbiome of SMH patients vs voluntheers — at baseline
    For each sample, the bacterial profiles determined by real time PCR, will be described and compared as follows: seborrheic macular hypopigmented lesions versus same anatomic area in healthy volunteers.

Trial sites (3)

FacilityCityRegionStatus
CHU de Nice - Hôpital de l'Archet Nice Alpes-Maritimes
Hôpital Louis Pasteur, hôpitaux Civils de Colmar Colmar Colmar
Hôpital Saint-Louis - APHP Paris Île-de-France Region
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06908889 on ClinicalTrials.gov ↗ ← All trials in France